ArticleBritish journal of cancer2014
Prognostic significance of CD44 variant 2 upregulation in colorectal cancer.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Aronia Berry Extract Inhibits Cancer Stemness and Overcomes 5-Fluorouracil Resistance by Targeting TLR3/NF-κB Signaling in Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Article
- MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.Cancer research · 2026Article
- CD44: A New Prognostic Marker in Colorectal Cancer?Cancers · 2024Review
- Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies.International journal of molecular sciences · 2024Article
- Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights.Current pharmaceutical design · 2024Review
- Review
- A Narrative Review on CD44's Role in Glioblastoma Invasion, Proliferation, and Tumor Recurrence.Cancers · 2023Review
- Article
- Review
- Melatonin and andrographolide synergize to inhibit the colospheroid phenotype by targeting Wnt/beta-catenin signaling.Journal of pineal research · 2022Article
- Cancer stem cell markers CD44v9+/CD133- are associated with low apoptosis in both sporadic and ulcerative colitis-associated colorectal cancers.Histology and histopathology · 2022Article
- Overexpression of CBS/HCancer cell international · 2022Article
- CD44v6+ Hepatocellular Carcinoma Cells Maintain Stemness Properties through Met/cJun/Nanog Signaling.Stem cells international · 2022Article
- Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.Theranostics · 2022Article
- CD44: A Multifunctional Mediator of Cancer Progression.Biomolecules · 2021Review
- Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits.Experimental hematology & oncology · 2021Review
- Extracellular matrix and its therapeutic potential for cancer treatment.Signal transduction and targeted therapy · 2021Review
- The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma.Genes & development · 2021Article
- The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD133 and CD44 are putative cancer stem cell (CSC) markers in colorectal cancer (CRC). However, their clinical significance is currently unclear. Here, we evaluated primary CRC cell isolates to determine the significance of several CSC markers, including CD133 and CD44, as predictors of tumourigenesis and prognosis.
methodsCD133- and CD44-positive cells from fresh clinical samples of 77 CRCs were selected by flow cytometric sorting and evaluated for tumourigenicity following subcutaneous transplantation into NOD/SCID mice. Cancer stem cell marker expression was examined in both xenografts and a complementary DNA library compiled from 167 CRC patient samples.
resultsCD44(+), CD133(+) and CD133(+)CD44(+) sub-populations were significantly more tumourigenic than the total cell population. The clinical samples expressed several transcript variants of CD44. Variant 2 was specifically overexpressed in both primary tumours and xenografts in comparison with the normal mucosa. A prognostic assay using qRT-PCR showed that the CD44v2(high) group (n=84, 5-year survival rate (5-OS): 0.74) had a significantly worse prognosis (P=0.041) than the CD44v2(low) group (n=83, 5-OS: 0.88).
conclusionsCD44 is an important CSC marker in CRC patients. Furthermore, CRC patients with high expression of CD44v2 have a poorer prognosis than patients with other CD44 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.